EUVIMEDEUVIMED entdecken
Crossref

Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials

Florence Delestre, Pierre Charles, Alexandre Karras, Christian Pagnoux, Antoine Néel, Pascal Cohen, Olivier Aumaître, Stanislas Faguer, Pierre Gobert, François Maurier, Maxime Samson, Pascal Godmer und 27 weitere

Annals of the Rheumatic Diseases · 2024-02 · 83 (2) · 233-241

DOI: 10.1136/ard-2023-224623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2024-02. Verfasst von Florence Delestre und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: French Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achieved a complete remission after induction therapy. Patients treated with 36-month RTX received either a fixed or a tailored regimen for the first 18 months and a fixed regimen for the last 18 months (36-month fixed/fixed RTX and 36-month tailored/fixed RTX, respectively). METHODS: The Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trials sequentially compared: 18-month fixed-schedule RTX versus AZA (MAINRITSAN); 18-month fixed-schedule RTX versus 18-month tailored-RTX (MAINRITSAN2); and extended therapy to 36 months with four additional RTX infusions after MAINRITSAN2 versus placebo (MAINRITSAN3). Patients were then followed prospectively through month 84 and their data were pooled to analyse relapses and adverse events. The primary endpoint was relapse-free survival at month 84. RESULTS: 277 patients were enrolled and divided in 5 groups: AZA (n=58), 18-month fixed-schedule RTX (n=97), 18-month tailored-RTX (n=40), 36-month tailored/fixed RTX (n=42), 36-month fixed/fixed RTX (n=41). After adjustment for prognostic factors, 18-month fixed-schedule RTX was superior to AZA in preventing major relapses at month 84 (HR 0.38, 95% CI 0.20 to 0.71). The 18-month tailored-RTX regimen was associated with an increased risk of major relapse compared with fixed-schedule regimen (HR 2.92, 95% CI 1.43 to 5.96). The risk of major relapse was similar between 36-month fixed/fixed and 18-month fixed-RTX (HR 0.69, 95% CI 0.38 to 1.25). CONCLUSIONS: According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. However, as this study was underpowered to make this comparison, further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansRituximabAzathioprineAntibodies, Antineutrophil CytoplasmicRecurrenceRemission InductionTreatment OutcomeImmunosuppressive Agents

Stichwörter der Autor:innen

Autoimmune DiseasesRituximabSystemic vasculitis

Substanzen

RituximabAzathioprineAntibodies, Antineutrophil CytoplasmicImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.
  • Université Paris Cité, Paris, France.
  • Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France.
  • Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France.
  • University of Toronto, Toronto, Ontario, Canada.
  • Vasculitis clinic, Mount Sinai Hospital, Toronto, Ontario, Canada.

Förderung

  • French Ministry of Health

Zitieren

APA

Delestre, F., Charles, P., Karras, A., Pagnoux, C., Néel, A., Cohen, P., Aumaître, O., Faguer, S., Gobert, P., Maurier, F., Samson, M., Godmer, P., Bonnotte, B., Cottin, V., Hanrotel-Saliou, C., Le Gallou, T., Carron, P. L., Desmurs-Clavel, H., Direz, G., …, & French Vasculitis Study Group (FVSG) (2024). Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Annals of the Rheumatic Diseases, 83(2), 233-241. https://doi.org/10.1136/ard-2023-224623

Vancouver

Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Annals of the Rheumatic Diseases. 2024;83(2):233-241. doi:10.1136/ard-2023-224623

BibTeX
@article{Delestre2024,
  author = {Delestre, Florence and Charles, Pierre and Karras, Alexandre and Pagnoux, Christian and Néel, Antoine and Cohen, Pascal and Aumaître, Olivier and Faguer, Stanislas and Gobert, Pierre and Maurier, François and Samson, Maxime and Godmer, Pascal and Bonnotte, Bernard and Cottin, Vincent and Hanrotel-Saliou, Catherine and Le Gallou, Thomas and Carron, Pierre-Louis and Desmurs-Clavel, Hélène and Direz, Guillaume and Jourde-Chiche, Noémie and Lifermann, Francois and Martin-Silva, Nicolas and Pugnet, Grégory and Quéméneur, Thomas and Matignon, Marie and Benhamou, Ygal and Daugas, Eric and Lazaro, Estibaliz and Limal, Nicolas and Ducret, Maïzé and Huart, Antoine and Viallard, Jean-François and Hachulla, Eric and Perrodeau, Elodie and Puechal, Xavier and Guillevin, Loïc and Porcher, Raphaël and Terrier, Benjamin and French Vasculitis Study Group (FVSG), French Vasculitis Study Group (FVSG)},
  title = {Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials},
  journal = {Annals of the Rheumatic Diseases},
  year = {2024},
  volume = {83},
  number = {2},
  pages = {233--241},
  doi = {10.1136/ard-2023-224623}
}
Kostenlos starten →